Cryptococcosis is a severe fungal infection affecting immunocompromised individuals, with treatment limited to FLZ, AMB, and FC. This study investigated the antifungal potential of fluconazole (FLZ)-, amphotericin B (AMB)-, 8-hydroxyquinoline (8HQ)-, and clioquinol (CQ)-based combinations against Cryptococcus neoformans and C. gattii. Drug interactions were assessed by checkerboard assay, followed by time–kill curves, irritability, toxicity, and virulence factors inhibition tests. The FLZ + AMB combination showed weak synergism, whereas FLZ combined with CQ or 8HQ exhibited strong synergistic effects (p < 0.001) at low concentrations (0.125–0.25 µg/mL), up to three times greater than those of FLZ + AMB. This effect persisted across other strains, including less FLZ-susceptible isolates. Moreover, FLZ + CQ inhibited melanin production in both species without causing significant irritability or toxicity in the tested models. These results indicate that combining drugs with distinct mechanisms of action can enhance antifungal efficacy while potentially reducing treatment doses. The FLZ + CQ/8HQ combinations represent promising candidates for future in vivo models for therapeutic evaluation.
Bazana et al. (Wed,) studied this question.